<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02226458</url>
  </required_header>
  <id_info>
    <org_study_id>EPI743-14-025</org_study_id>
    <nct_id>NCT02226458</nct_id>
  </id_info>
  <brief_title>An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder</brief_title>
  <acronym>Autism</acronym>
  <official_title>An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that EPI-743 may provide clinical benefit to children with
      Autism Spectrum Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Exploratory Open Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children with Autism
      Spectrum Disorder
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study was halted prior to enrolling.
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Change in plasma levels of reduced and oxidized glutathione from baseline to six months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change in language skills as assessed by change from baseline to six months on the Clinical Evaluation of Language Fundamentals or Preschool Language Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to six months in adaptive behavior and social skills as assessed by the Vineland Adaptive Behavior Scale-Second Edition (VABS), Social Responsiveness Scale (SRS), and computerized eye movement analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to six months in stereotyped behavior and associated ASD symptoms as assessed by Aberrant Behavior Checklist (ABC), The Ohio Autism Clinical Impression Scale (OACIS), Repetitive Behavior Scale - Revised (RBS-R) and Autism symptoms questionnaire (ASQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to six months in gastrointestinal function as assessed by Symptom Diary (stool frequency, abdominal symptoms and medications) and six-item GI severity index (6-GSI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to six months in caregiver strain experienced by parents of children with emotional and behavioral disorders as assessed by Caregiver Strain Questionnaire (CGSQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to six months in intellectual function, attention and memory as assessed by Leiter-R test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Change from baseline to six months in biomarkers of oxidative stress</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint</measure>
    <time_frame>6 months</time_frame>
    <description>Pharmacokinetic Assessment of EPI-743 including maximal plasma concentration (Cmax), area under plasma concentration curve (AUC), apparent oral clearance, apparent volume of distribution and time to peak concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>8 months</time_frame>
    <description>To examine the safety of EPI-743 in subjects with Autism Spectrum Disorder by examining drug-related adverse and serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Autism Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>EPI-743</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg oral solution three times per day, maximum of 200 mg per dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743</intervention_name>
    <arm_group_label>EPI-743</arm_group_label>
    <other_name>Vincerinone TM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Autism Spectrum Disorder as defined by the DSM-V criteria for ASD and a
             gold-standard diagnostic evaluation for ASD such as the Autism Diagnostic Observation
             Schedule (ADOS) and/or the Autism Diagnostic Interview - Revised (ADI-R)

          2. Male or female, 3 years to 14 years of age

          3. Abnormal glutathione cycle biomarkers (GSH/GSSG in plasma&lt;8.0)

          4. Language impairment (as defined by the CELF-2 or CELF-4 screener)

          5. Ability to complete language assessment (using either CELF or PLS)

          6. Subject or subject's guardian able to consent and comply with protocol requirements

          7. Abstention from use of Coenzyme Q10, vitamin E, lipoic acid, folinic acid, other forms
             of folic acid above recommended daily allowance (RDA), and idebenone 2 months prior to
             treatment with EPI-743 and for duration of study

          8. Stable regimen of medication and supplements for 2 months prior to enrollment and
             duration of the study

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil

          2. Allergy to vitamin E

          3. Clinical history of bleeding or abnormal baseline PT/PTT

          4. Use of anticoagulant medications

          5. Participation in any other interventional study within 90 days of treatment.

          6. Use of antipsychotic medications

          7. Moderate to severe positive response on ABC irritability subscale on questions:
             Injures self on purpose, is aggressive to other children or adults (verbally or
             physically), deliberately hurts himself/ herself, and/or does physical violence to
             self

          8. Severe impairment as defined as a Vineland Adaptive Behavioral Scales composite
             standard score of &lt;40

          9. Patients with genetic disease that gives rise to ASD (e.g. Rett syndrome, Down
             syndrome, fragile x syndrome)

         10. Abnormal liver function tests two times the upper limit of normal or renal
             insufficiency with creatinine levels two times the upper limit of normal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2014</study_first_submitted>
  <study_first_submitted_qc>August 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2014</study_first_posted>
  <last_update_submitted>March 9, 2015</last_update_submitted>
  <last_update_submitted_qc>March 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Mitochondrial Disorders</keyword>
  <keyword>EPI-743</keyword>
  <keyword>EPI743</keyword>
  <keyword>Rett syndrome</keyword>
  <keyword>Angelman syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

